Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific (2', 5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5'-(4'-amino-1',2'-oxathiole-2', 2'-dioxide))-beta-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors

Human immunodeficiency virus type 1 (HIV-1) is highly inhibited by the newly discovered class of necleoside analogues. The nucleoside analogues target the nonsubstrate binding site of HIV-1 reverse transcriptase (RT). The nucleotide analogues called TSAO are experimented upon to determine the resistivity of the HIV-1. The HIV-1 strains, which resist the TSAO nucleoside derivatives, are sensitive to the other HIV-1 specific nucleoside derivatives. Rapid degradation occurs in the HIV-1 RT, where the Glu-138 to Lys substitution was introduced by the site directed mutagenesis. However, stability was noticed in the HIV-1 Rt having the Glu-138 to Lys substitution.